Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

European Journal of Cancer

Volumn 47, Issue 15, 2011, Pages 2306-2314

  Thuss Patience, Peter C ^a   Kretzschmar, Albrecht ^b,e   Bichev, Dmitry ^a   Deist, Tillman ^c   Hinke, Axel ^d   Breithaupt, Kirstin ^a   Dogan, Yasemin ^a   Gebauer, Bernhard ^a   Schumacher, Guido ^a,f   Reichardt, Peter ^a,g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c Innere Medizin II M S Gastroenterologie   (Germany)

^d WiSP Wissenschaftlicher Service Pharma GmbH   (Germany)

^e Klinikum St Georg   (Germany)

^f KLINIKUM BRAUNSCHWEIG   (Germany)

^g HELIOS Klinikum Bad Saarow   (Germany)

Author keywords

Best supportive care; Gastric cancer; Irinotecan; Phase III study; Second line

Indexed keywords

CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; PACLITAXEL;

ADULT; AGED; BEST SUPPORTIVE CARE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; ELECTROCORTICOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053341349     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.002     Document Type: Article

References (29)

1. F. Kamangar, G.M. Dores, and W.F. Anderson Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 14 2006 2137 2150 (Pubitemid 46655601)
2. D.M. Parkin, P. Pisani, and J. Ferlay Global Cancer Statistics CA Cancer J Clin 49 1999 33 64 (Pubitemid 29094960)
3. A.M. Murad, F.F. Santiago, and A. Petroianu Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 1993 37 41 (Pubitemid 23182046)
4. S. Pyrhonen, T. Kuitunen, P. Nyandoto, and M. Kouri Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 1995 587 591
5. Scheithauer W, Kornek G, Zeh B. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. In: Second International Conference on Biology, Prevention, and Treatment of GI Malignancy, Köln, Germany; 1995. p. 68.
6. B. Glimelius, K. Ekstrom, and K. Hoffman Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 1997 163 168 (Pubitemid 27112884)
7. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
8. E. Van Cutsem, Y. Kang, and H. Chung Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) J Clin Oncol 27 2009 18s (suppl; abstr LBA4509)
9. W. Koizumi, H. Narahara, and T. Hara S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 3 2008 215 221 (Epub 2008 Feb 20)
10. O. Kanat, T. Evrensel, and O. Manavoglu Single-agent irinotecan as second-line treatment for advanced gastric cancer Tumori 89 2003 405 407 (Pubitemid 37279923)
11. J.H. Chun, H.K. Kim, and J.S. Lee Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy Jpn J Clin Oncol 34 2004 8 13 (Pubitemid 43118052)
12. L. Assersohn, G. Brown, and D. Cunningham Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Ann Oncol 15 2004 64 69 (Pubitemid 38145530)
13. S.T. Kim, W.K. Kang, and J.H. Kang Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer Br J Cancer 92 2005 1850 1854 (Pubitemid 40826132)
14. F. Giuliani, V. Gebbia, and F. De Vita Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.) Anticancer Res 23 2003 4219 4222 (Pubitemid 37474923)
15. C. Kunisaki, T. Imada, and R. Yamada Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma Anticancer Res 25 2005 2973 2977
16. M. Stahl, C. Muller, W. Koster, and H. Wilke Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy Onkologie 28 2005 499 502 (Pubitemid 41420846)
17. D. Wilson, L. Hiller, and J.I. Geh Review of second-line chemotherapy for advanced gastric adenocarcinoma Clin Oncol (R Coll Radiol) 17 2 2005 81 90 (Pubitemid 40309884)
18. C.H. Köhne, R. Catane, and B. Klein Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial Br J Cancer 89 6 2003 997 1001 (Pubitemid 37239201)
19. M. Dank, J. Zaluski, and C. Barone Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naïve patients with advanced adenocarcinoma of the stomach or osophagogastric junction Ann Oncol 19 2008 1450 1457
20. O. Bouche, J.L. Raoul, and F. Bonnetain Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803 J Clin Oncol 22 2004 4319 4328 (Pubitemid 41199650)
21. C.S. Fuchs, M.R. Moore, and G. Harker Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 5 2003 807 814 (Pubitemid 46606439)
22. E. Van Cutsem, L. Dirix, and J.L. Van Laethem Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study Br J Cancer 92 6 2005 1055 1062 (Pubitemid 40546669)
23. J.M. Lachin, and M. Foulkes Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance and stratification Biometrics 42 1986 507 519
24. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Ass 53 1958 457 481
25. R. Peto, and J. Peto Asymptotically efficient rank invariation test procedures (with discussion) J R Stat Soc 135 1972 185
26. World Health Organization WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48 1979 World Health Organization Geneva, Switzerland
27. Y. Kang, A. Ohtsu, and E. Van Cutsem AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine, cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) J Clin Oncol 28 2010 18s (suppl; abstr LBA4007)
28. V. Catalano, F. Graziano, and D. Santini Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 99 2008 1402 1407
29. R. Wesolowski, C. Lee, and R. Kim Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 10 9 2009 903 912